TG THERAPEUTICS, INC. Revenue Disclosure

NOTE 2 - REVENUE 

 

As discussed in Note 1, revenues are recognized under the guidance of ASC 606. The following table presents the Company's disaggregated revenue for the periods presented (in thousands):

 

(in thousands)		Year ended December 31,
		2025				2024				2023
Total product revenue, net		$	606,928			$	313,728			$	92,005
License Revenue			152				152				140,153
Milestone Revenue			—				12,500				—
Royalty Revenue			5,615				801				—
Other Revenue			3,592				1,823				1,504
Total Revenue		$	616,287			$	329,004			$	233,662

 

Product revenue, net

 

The following table presents the Company's disaggregated BRIUMVI revenue by geography for the periods presented:

 

(in thousands)		Year ended December 31,
		2025				2024				2023
BRIUMVI
U.S.		$	594,105			$	310,023			$	88,786
International			12,823				3,705				3,219
Worldwide		$	606,928			$	313,728			$	92,005

 

The Company began shipping BRIUMVI to its U.S. customers in January 2023, and BRIUMVI to its ex-U.S. licensing partner, Neuraxpharm, in November 2023.

 

As of  December 31, 2025, gross-to-net accruals of approximately $20.5 million and $40.9 million are included on the consolidated balance sheets within accounts receivable, net, and accounts payable and accrued expenses, respectively. As of  December 31, 2024, gross-to-net accruals of approximately $11.1 million and $20.9 million were included on the consolidated balance sheets within accounts receivable, net, and accounts payable and accrued expenses, respectively.

 

The Company primarily sells BRIUMVI through specialty distributors. The following table summarizes customers that represented 10% or more of gross product revenue for the years ended  December 31, 2025, 2024 and 2023:

 

		Twelve months ended December 31,
		2025				2024				2023
Customer 1			42	%			42	%			41	%
Customer 2			26	%			29	%			31	%
Customer 3			18	%			15	%			16	%
Customer 4			12	%			14	%			13	%

 

The following table summarizes the customers with amounts due that represent 10% or more of the accounts receivable associated with the Company’s product sales as of  December 31, 2025 and 2024:

 

		Twelve months ended December 31,
		2025				2024
Customer 1			38	%			32	%
Customer 2			18	%			25	%
Customer 3			27	%			25	%
Customer 4			15	%			17	%

 

License, Milestone, Royalty and Other Revenue

 

License, milestone, royalty and other revenue consist primarily of recognition of consideration received under the ex-U.S. commercialization agreement (the Commercialization Agreement) with Neuraxpharm. Refer to Note 10 - License Agreements for a description of the Commercialization Agreement and for further information of the accounting in accordance with ASC 606.